Article Contents ::
- 1 The Brand Name LAMIVIR ORAL Has Generic Salt :: Lamivudine
- 2 LAMIVIR ORAL Is From Company Cipla Priced :: Rs. 99.99
- 3 LAMIVIR ORAL have Lamivudine is comes under Sub class Anti Retrovirals (Drugs for HIV) of Main Class Anti Infectives
- 4 Main Medicine Class:: Anti Infectives Sub Medicine Class :: Anti Retrovirals (Drugs for HIV)
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name LAMIVIR ORAL Has Generic Salt :: Lamivudine
LAMIVIR ORAL Is From Company Cipla Priced :: Rs. 99.99
|Salt Name : OR Generic Name||Form||Price : MRP /Probable||Packing|
Indications for Drugs ::
HIV infection, Chronic hepatitis B
Drug Dose ::
Oral HIV infection Adult: 150 mg bid or 300 mg once daily, in combination with other antiretrovirals. Child: 3 mth-12 yr: 4 mg/kg bid. Max: 300 mg/day. Renal impairment: Dialysis patients: Not recommended. CrCl (ml/min) 30-49 1st dose 150 mg, then 150 mg once daily. 15-29 1st dose 150 mg, then 100 mg once daily. 5-14 1st dose 150 mg, then 50 mg once daily. <5 1st dose 50 mg, then 25 mg once daily. Chronic hepatitis B Adult: 100 mg once daily. For patients with concomitant HIV infection: 300 mg once daily or in 2 divided doses. Child: >2 yr: 3 mg/kg once daily. Max: 100 mg/day. Renal impairment: Haemodialysis patients: Dose adjustment in accordance with CrCl. Peritoneal dialysis patients: Not recommended. CrCl (ml/min) 30-49 1st dose 100 mg, then 50 mg once daily. 15-29 1st dose 100 mg, then 25 mg once daily. 5-14 1st dose 35 mg, then 15 mg once daily. <5 1st dose 35 mg, then 10 mg once daily. Contraindication ::
Drug Precautions ::
Discontinue use if there is rapid increase in aminotransferase levels, progressive hepatomegaly, or metabolic or lactic acidosis of unknown origin. Discontinue use if clinical signs, symptoms or lab abnormalities suggestive of pancreatitis develop. Hepatomegaly or other risk factors for hepatic impairment. Monitor hepatic function in chronic hepatitis B patients. Exclude HIV infection prior to hepatitis B therapy. Renal impairment. Pregnancy.
Drug Side Effects ::
Abdominal pain, nausea, vomiting, diarrhoea, insomnia, cough, nasal symptoms, arthralgia, muscle pain, headache, fever, rash, alopecia, malaise, increased creatinine phosphokinase and alanine aminotransferase, peripheral neuropathy. Rarely rhabdomyolysis, pancreatitis, hepatitis. Neutropenia and anaemia (in combination with zidovudine), thrombocytopenia, increases in LFTs. Paronychia. Angioedema, urticaria, and anaphylactoid reaction.Potentially Fatal: Lactic acidosis associated with severe hepatomegaly and hepatic steatosis.
Pregnancy category ::
Drug Mode of Action ::
Lamivudine, a nucleoside analogue, is phosphorylated in the body to the active triphosphate form. In the active form, it inhibits hepatitis B virus polymerase and HIV reverse transcriptase enzymes.
Drug Interactions ::
Renal excretion may be inhibited by high doses of trimethoprim (co-trimoxazole). May antagonise the antiviral action of zalcitabine.